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Abstract
Background: The aim of this study is to analyse the clinical features of HIV patients with cytomegalovirus retinitis
(CMVR) developing immune recovery uveitis (IRU) while on highly active antiretroviral therapy (HAART) and to
identify the risk factors, visual outcomes and complications of IRU.
Results: Majority (n = 26, 86.7 %) of patients were male, with 76.7 % (n = 23) of patients having bilateral disease.
Twenty-seven eyes (50.9 %) had both anterior uveitis and vitritis. The median CD4 at IRU was 210 cells/μL
(IQR 140–279), with 86.7 % having CD4 >100 cells/μL. The median duration from initiation of HAART to IRU was
significantly different between those <50 years old (median 763 days, IQR 174–1872 days) and those ≥50 years
old (median 161 days, IQR 84.5–278 days). Fourteen eyes (26.4 %) had loss of one or more Snellen lines visual
acuity at 6 months while the rest maintained or improved vision. Complications developed in 21 eyes, with cataract
(66.7 %), glaucoma and ocular hypertension (33.3 %) being the most common. The risk of complications was
associated with the absolute difference in CD4 counts at IRU and at HAART commencement (p = 0.041). Age was also
negatively associated with the duration from HAART to IRU (p = 0.005, Spearman’s rho coefficient = −0.503).
Conclusions: It is common to have both anterior uveitis and vitritis in IRU. There was a positive association between
the increase in CD4 from HIV to IRU diagnoses and the risk of developing complications. Younger patients appeared to
develop IRU later than older patients after HAART, suggesting that long-term follow-ups are essential for these patients.
Keywords: Immune recovery uveitis, Human immunodeficiency virus, Cytomegalovirus retinitis, Highly active
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Background
Immune reconstitution inflammatory syndrome (IRIS) is
a group of disorders that has been described in HIV
patients who are on highly active antiretroviral therapy
(HAART). This phenomenon is associated with a para-
doxical or exaggerated reactivation of the immune
system in the background of a wide range of pathologies
such as Kaposi’s sarcoma, tuberculosis, cryptococcal
infection and cytomegalovirus [1].
Immune recovery uveitis (IRU) is one manifestation
where immune-deficient patients with prior cytomegalo-
virus retinitis (CMVR) experience an increase in intraoc-
ular inflammation following HAART. It is presumed to
be mediated by the recovery of immune responses spe-
cific to residual cytomegalovirus (CMV) antigens in the
eye [2]. IRU is an important cause of visual morbidity in
HIV-infected patients with CMVR in the era of HAART
[3]. Although immune recovery associated with HAART
has allowed some patients to discontinue specific anti-
CMV therapy, the rejuvenated immune response can be
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associated with chronic sight-threatening inflammation.
Visual complications of IRU include cataract, cystoid
macular edema (CME), glaucoma and epiretinal mem-
brane formation [4–10]. Reported risk factors include a
low CD4 count at the time of initiation of HAART and
larger areas of CMVR [3]. With the rising prevalence of
HIV patients and greater accessibility and availability of
HAART worldwide, IRU is an increasingly important
disease entity. We aim to analyse the characteristics of
IRU in HIV patients on HAART in Singapore, to identify
risk factors for the development of IRU and to dete-
rmine their visual outcomes.
Methods
A retrospective analysis of clinical records of 30
consecutive IRU patients presenting to the Eye Clinic at
the Communicable Disease Centre (CDC), Singapore,
between March 2004 and September 2009 was per-
formed. Ethics approval was obtained from the local
ethics review board in accordance with the Declaration
of Helsinki.
The CDC is the main site of referral and management
for HIV in Singapore. IRU was diagnosed when there is
an increase in any form of intraocular inflammation
from an inactive state of CMV retinitis secondary to
immune recovery after initiation of HAART, as evi-
denced by an increase in CD4 count by 50 or more
cells/μL from the nadir CD4 count to a level of more
than 100 cells/μL [3]. Despite a CD4 count of less than
100 cells/μL at diagnosis, a small subset of patients are
also deemed to have IRU. These patients would have an
increase in intraocular inflammation, which is correlated
with a rise in CD4 count that could not be clinically
attributed to a reactivation of CMVR.
All of the patients had prior CMV retinitis treated
with an intravitreal ganciclovir regimen, as previously
described [11]. Two patients were also treated with
intravenous ganciclovir, and one received oral valganci-
clovir. Patients with concomitant infective or other
autoimmune causes of inflammation were excluded
from this study. All patients underwent Snellen best-
corrected visual acuity (BCVA) assessment, tonometry
and dilated slit-lamp biomicroscopy and indirect
ophthalmoscopy examinations. Clinical data obtained
included patient demographics (age, gender and ethni-
city); duration between HIV, CMVR and IRU diagnoses;
BCVA at presentation and at 6 months; corresponding
CD4 counts and CD4/CD8 ratios; duration from initi-
ation of HAART to IRU development; presenting signs
and symptoms; CMVR zone and area of involvement;
IRU severity and location; and treatment regimes. The
location of CMVR lesion in each eye was categorised
into three zones. Zone 1 was defined as the area within
1500 μm of the optic nerve or within 3000 μm of the
fovea. Zone 2 extended from the borders of zone 1 to
the vortex veins, and zone 3 involves the retina perip-
heral to zone 2 [12]. For patients with CMVR involving
multiple zones, the zone nearest to the macula was
reported.
Descriptive analysis was performed for demographics,
visual acuity, complications and IRU and CMVR charac-
teristics, with categorical variables summarised with
frequencies and percentages and continuous variables
summarised as either means with standard deviations
or medians with ranges. Spearman’s rho was calculated
to check for association between CD4 counts and dura-
tions. Independent sample t test and Mann-Whitney U
test were used for comparison of age, durations and
CD4 counts between patient groups with and without
complications, respectively. Logistic regression was
used to understand the relationship between variables.
A p value less than 0.05 was considered to indicate stat-
istical significance. Data analysis was carried out using
IBM SPSS Statistics (version 19, IBM Corp., NY, USA).
Results
IRU characteristics
Twenty-six patients (86.7 %) were male, and the median
age at IRU diagnosis was 49.5 years old (interquartile
range (IQR) 41–56 years). Chinese patients (n = 25)
formed the majority, corresponding to the ethnic distri-
bution of the local population [13]. Only eyes (n = 53)
with previous CMVR, in this cohort, developed IRU.
Twenty-three patients (76.7 %) presented with bilateral
IRU. Twenty-seven IRU eyes (50.9 %) presented with
both anterior uveitis and vitritis. Twenty-two IRU eyes
(41.5 %) presented with anterior uveitis alone, while one
eye (1.9 %) presented with only vitritis. The median CD4
count at HIV diagnosis of these patients was 20 cells/μL
(IQR 15.0–62.0), while the median CD4 count at IRU
diagnosis was 210 cells/μL (IQR 140–279), with 86.7 %
having CD4 >100 cells/μL. Two of the four patients with
CD4 count less than 100 cells/μL had more than 50
cells/μL increase in CD4 count at IRU diagnosis. The
median increase in CD4 at IRU was 155.5 cells/μL
(IQR 66.0–228.0). The median duration from HIV
diagnosis to initiation of HAART was 100.5 days
(IQR 61.0–210.0), while the median duration from
initiation of HAART to IRU was 214 days (IQR
118.0–763.0). Thirteen IRU patients (43.3 %) were
asymptomatic at presentation. Of the remaining 17
IRU patients, the most common symptom was blur-
ring of vision alone (n = 11, 36.7 %) followed by
floaters (n = 4, 13.3 %). All patients were treated with
topical steroids, with eight patients requiring add-
itional sub-tenon steroid injections and two patients
receiving oral steroids (Tables 1 and 2).
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CMVR characteristics
All of the patients had CMVR in at least one eye. Fifty-
three of the 60 eyes (88.3 %) had previous CMVR. The
median duration from HIV diagnosis to CMVR was
283.0 days (IQR 142.0–539.5), while the median
duration from CMVR diagnosis to anti-CMVR treatment
was 0 days (range −2 to 16), with 24 patients receiving
treatment on the same day as CMVR diagnosis. The
median CD4 count at CMVR diagnosis in our patients
was 28.5 cells/μL (IQR 11.0–60.5). Most eyes (n = 23,
43.4 %) had previous CMVR involvement in zone 2. This
was followed by zone 1 CMVR involvement in 15 eyes
(28.3 %) and zone 3 involvement in 11 eyes (20.8 %).
The majority of eyes (n = 40, 75.5 %) had <25 % area of
involvement, while nine eyes (17.0 %) had 25–50 % area
of involvement and four eyes (7.5 %) had >50 % area of
involvement (Table 3).
Visual outcome
The BCVA of IRU patients was assessed at diagnosis of
IRU and at 6 months. The range of visual acuity at pres-
entation was 6/4 to NPL, with 19 eyes (35.8 %) having
BCVA worse than 6/12. At 6 months, 18 eyes (34 %)
had BCVA worse than 6/12. Six (11.3 %) and two eyes
(3.8 %) had a loss of one and two Snellen lines, respect-
ively. Six eyes (11.3 %) had a loss of three Snellen lines
or more. These were due to glaucoma, cataract or per-
sistent inflammation. The remaining patients had visual
acuities that were maintained or better than at IRU
presentation (Table 4).
Complications
Twenty-one eyes (39.6 %) developed complications. The
most common complication was cataract (n = 14, 66.7 %),
followed by glaucoma and ocular hypertension (n = 7,
33.3 %). There were no cases of CME during the
course of this study. Mann-Whitney U test showed
an association between the presence of complications
and the absolute difference in CD4 counts at IRU
and at HAART commencement (p = 0.041). For every
50 cells/μL increase in CD4 at IRU diagnosis, patients
were 1.28 times more likely to develop complications
(p = 0.084). Although not statistically significant, the
higher CD4 count at IRU diagnosis also appeared to
be associated with the development of complications
(p = 0.057). CMVR characteristics (zone and area of
involvement) were not found to be associated with
Table 1 IRU characteristics









Age, years; mean (SD)
At IRU diagnosis 47.9 (10.7)
CD4 count, cells/μL; median (IQR)
At HAART commencement 20.0 (15.0–62.0)
At IRU diagnosis 210.0 (139.8–289.5)
At CMVR diagnosis 28.5 (10.5–61.8)
Difference from HAART to IRU diagnosis 155.5 (66.0–228.0)
Duration, days; median (IQR)
From HIV diagnosis to HAART commencement 100.5 (61.0–210.0)
From HAART initiation to IRU diagnosis 214.0 (118.0–763.0)
From CMVR diagnosis to IRU diagnosis 136.5 (26.0–618.5)
Table 2 IRU-presenting characteristics
Number of patients, n 30
Symptoms, n (%)
Blurring of vision 11 (36.7)
Floaters 4 (13.3)
Pain 1 (3.3)
Blurring of vision and floaters 1 (3.3)
None 13 (43.3)
Number of IRU eyes, n 53
Presenting features, n (%)
Anterior uveitis alone 22 (41.5)
Vitritis alone 1 (1.9)
Anterior uveitis and vitritis 27 (50.9)
Anterior uveitis and vitreous haemorrhage 2 (3.8)
Vasculitis 1 (1.9)
Table 3 CMV characteristics
Number of eyes, n 53
Location, n (%)
Zone 1 15 (28.3)
Zone 2 23 (43.4)
Zone 3 11 (20.8)
CMVR involvement retinal area, n (%)
<25 % 40 (75.5)
25–50 % 9 (17.0)
>50 % 4 (7.5)
Duration, days; median (IQR)
From HIV diagnosis to CMVR diagnosis 283.0 (142.0–539.5)
From CMVR diagnosis to anti-CMVR treatment 0.0 (0.0–0.0)
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the development of complications (p = 0.534 and p = 0.715,
respectively).
Risk factors
Age was found to be negatively associated with the
duration taken to develop IRU after initiation of HAART
(p = 0.005, Spearman’s rho coefficient = −0.503). Median
duration from HAART initiation to development of IRU
was 763 days (IQR 174–1872 days) and 161 days (IQR
84.5–278 days) for patients <50 years old and patients
≥50 years old, respectively. The CD4 counts at HIV
diagnosis, at initiation of HAART and at IRU diagnosis
were not found to be significantly associated with the
duration from HAART to IRU diagnosis. Both the abso-
lute and the percentage increase in CD4 counts were
also not significantly associated with the duration taken
to develop IRU after initiation of HAART. CMVR zone
or area of involvement was not found to be associated
with the duration of IRU development from initiation of
HAART.
Discussion
HIV-related mortality has decreased dramatically in the
era of HAART. However, it is now evident that the com-
mencement of HAART can also potentially lead to consid-
erable morbidity and mortality in the form of IRIS,
especially in the first 6 months [14]. IRU is an important
presentation in this broad disease group which also
includes tuberculosis-associated IRIS and Kaposi’s sar-
coma IRIS [1]. This is the first paper discussing the
characteristics of IRU and its complications in Singapore
and Southeast Asia. As the Communicable Disease Centre
in Singapore manages and treats the majority of local HIV
patients [15], our patient cohort is highly reflective of IRU
diagnosed locally. The number of HIV-positive patients in
Singapore has been gradually increasing, with 454 newly
diagnosed cases in 2013 and a total of 6229 patients diag-
nosed since 1985 [16]. The number of patients with
CMVR has increased correspondingly, with 224 patients
diagnosed at the CDC from 2005 to 2010 [17]. IRU is
most commonly associated with previous CMVR in
patients who have experienced immune recovery.
Similar to previous studies, vitritis is the most com-
mon presentation in our cohort [5, 10, 18, 19]. There are
also a significant proportion of patients who had an-
terior uveitis. Although anterior uveitis is commonly
reported [5, 9, 10, 20], most studies have focused their
diagnosis of IRU on the presence of vitritis and asso-
ciated CME [4, 6, 9, 18, 19].
Patients with larger areas of CMVR involvement were
reported to have higher risk of IRU development [9]. In
contrast, the majority of eyes in our cohort had <25 % area
of previous CMVR involvement. Arevalo et al. did not find
an association between CMVR area and risk of IRU deve-
lopment [21]. This suggests that small CMVR lesions are
common and eyes without large areas of CMVR invo-
vement are similarly at risk of developing IRU.
Within our cohort, we did not find any association
between CD4 counts at HIV diagnosis, at initiation of
HAART or at IRU diagnosis, with the development of
IRU. However, the duration from the initiation of
HAART to IRU was found to be longer in younger
patients (<50 years old). Hartigan-O’Connor et al. previ-
ously reported that IRU is most likely to develop in
patients with the greatest degree of immune dysfunction
prior to HAART [22]. Additionally, older age groups
have been correlated with quicker seroconversion to
AIDS in the pre-HAART era, as well as higher rates of
immunologic failure and persistent HIV viraemia in the
HAART era [23]. Thus, it is plausible that younger HIV
patients have a more intact immune system that may
not have such heightened sensitivity to CD4 T cell
responses, consequently delaying their development of
IRU until the occurrence of further immune dysfunction.
The most common complications of IRU in our cohort
were cataract formation, glaucoma and ocular hyperten-
sion. Our findings differ from other reports where CME
and epiretinal membrane were the most common com-
plications. For instance, Robinson et al. reported that of
the IRU eyes in their cohort, 91 % developed CME, 52 %
developed cataract and 30 % developed epiretinal mem-
brane [5]. Cataract, CME and epiretinal membrane
typically caused moderate visual loss [3, 5, 7].
No cases of CME were reported during the course of
this study. Although CME is often described and is a
serious sight-threatening complication of IRU, we believe
Table 4 Visual outcome
Number of affected eyes, n 53
Range of VA at IRU presentation, n (%)
6/6 to 6/12 34 (64.2 %)
6/15 to 6/45 12 (22.6 %)
6/60 or worse 7 (13.2 %)
Range of VA at 6-month follow-up post IRU diagnosis, n (%)
6/6 to 6/12 35 (66.0 %)
6/15 to 6/45 10 (18.9 %)
6/60 or worse 8 (15.1 %)
VA change from IRU diagnosis to 6-month follow-up, n (%)
Worsen by at least 3 lines 6 (11.3 %)
Worsen by 2 lines 2 (3.8 %)
Worsen by 1 line 6 (11.3 %)
No change 18 (34.0 %)
Improved by 1 line 7 (13.2 %)
Improved by 2 lines 6 (11.3 %)
Improved by at least 3 lines 8 (15.1 %)
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that it is not a common feature, especially if the inflam-
mation is treated earlier. This is particularly pertinent as
there is currently no consensus on the ideal time to start
treatment of IRU. In fact, the majority of studies have
suggested that mild and asymptomatic ocular inflamma-
tion usually resolves without treatment; treatment is
instituted in more severe inflammation and in patients
who become symptomatic [6, 8].
IRU has been described as a transient form of inflam-
mation [19]. Still, others report that the persistence of
inflammation in IRU is the cause of complications like
CME and epiretinal membrane [6, 18]. Based on our
findings, we propose the early treatment of ocular in-
flammation in IRU patients to prevent sight-threatening
complications of CME and epiretinal membrane. None-
theless, the judicious use of topical steroids in treating
asymptomatic patients must be balanced against the
possible complications of steroid use.
The risk of IRU complications was found to be higher
with greater CD4 count increase from HIV to IRU diag-
nosis. The greater inflammatory response mounted in
these immune reconstituted patients, together with a
robust increase in the number of viable T lymphocytes,
results in severe and chronic inflammation [24]. The
increased inflammatory response can lead to cataract
formation, raised intraocular pressure and glaucoma.
Conversely, the development of cataract and raised
intraocular pressure may also be the result of aggressive
steroid therapy, which is often instituted in these
patients. However, the mode of steroid therapy did not
appear to be associated with the risk of development of
complications in this study.
The presence of IRU at baseline was reported to be
associated with an increased risk of moderate vision loss
to 6/15 [3]. The visual outcome of our IRU patient
cohort was, however, fair with only eight eyes losing two
or more lines of Snellen VA. 73.6 % of eyes (n = 39) had
either maintained or improved in vision. The importance
of early diagnosis with aggressive and appropriate treat-
ment can improve and preserve vision. Moreover, a
number of patients were asymptomatic and were found
to have IRU only on routine follow-up examinations. All
HIV patients with treated CMVR should continue to
have regular reviews at the eye clinic at regular intervals,
even if they have high CD4 counts. Our study showed
the median time from commencement of HAART to
IRU development to be about 7 months. The longest
time taken was 8.8 years in a 25-year-old female.
Without regular follow-up, early recognition and treat-
ment, the visual outcomes of these patients may be less
favourable.
The main limitations of this study were its retrospect-
ive design and relatively small sample size. There was
also no control group. Unlike other studies, we did not
routinely perform angiogram on our patients. Hence, it
is possible that early CME not apparent on physical
examination was missed. Nonetheless, our cohort of pa-
tients was diagnosed consecutively from the CDC, which
is reflective of the HIV patient profile in Singapore, as
the CDC is the main centre for HIV treatment.
Conclusions
IRU is common and usually presents with vitritis. Early
treatment of ocular inflammation can prevent the devel-
opment of sight-threatening complications of IRU. The
most common complication is cataract formation, and
the risk of complications was positively associated with
the increase in CD4 count at IRU and HIV diagnosis.
Younger patients also appeared to develop IRU later
than older patients after HAART, emphasising that long-
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